Intranasal inhalation of beclomethasone dipropionate in the treatment of perennial rhinitis in adults.
Forty-eight perennial rhinitis patients completed a six weeks' open trial of intranasal beclomethasone dipropionate aerosol. Each received a daily dose of 400 micrograms. Thirty-five responded excellently, seven reported satisfactory improvement and six failed. This study indicated that patients with a demonstrable allergic component responded favorably. However, due to the wide margin of safety the authors suggest that it be tried on the non-infective perennial rhinitis with no demonstrable allergic component as well.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000150:complications; D001507:Beclomethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D004804:Eosinophils; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000473:pathology; D009666:Nose / Q000000981:diagnostic imaging / Q000382:microbiology; D011859:Radiography; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000188:drug therapy*; D012882:Skin Tests
D007073:Immunoglobulin E; D001507:Beclomethasone